MedTrace Logo

Drug-drug Interaction Study with GLPG3667 and Itraconazole in Healthy Subjects

NCT05272683 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2024-09-19

No results posted yet for this study

Summary

The main purpose of this study is to determine the effect of itraconazole on the amount of GLPG3667 that gets into the blood when the 2 drugs are administered together compared to when GLPG3667 is administered alone.

Conditions

  • Healthy

Interventions

DRUG

GLPG3667

On day 1 and day 8, participants will receive a single dose

DRUG

Itraconazole

On days 5 to 11, participants will receive itraconazole once daily

Sponsors & Collaborators

  • Galapagos NV

    lead INDUSTRY

Principal Investigators

  • Galapagos Study Director, MD · Galapagos NV

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-28
Primary Completion
2022-04-01
Completion
2022-04-22

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05272683 on ClinicalTrials.gov